SIX · ROP.SW
Roche Holding AG
CHF 403.30+CHF 1.60 (+0.4%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.64% below the high.
Loading market information…
NASDAQ · OBSV · USD
Stock price, earnings
Quote as of Mar 22, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
ObsEva S.A.’s quoted price sits in the lower half of its reported 52-week range, 95.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow ObsEva S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
ObsEva S.A. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for conditions affecting women's reproductive health and pregnancy. A key part of their development pipeline is Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, currently in Phase III clinical trials. This drug aims to mitigate pain associated with endometriosis and reduce heavy menstrual bleeding stemming from uterine fibroids in pre-menopausal women. Additionally, the company is progressing Ebopiprant, a selective oral prostaglandin F2a (PGF2a) receptor antagonist, through Phase II trials as a once-daily therapy for preterm labor occurring between 24 and 34 weeks of gestation. Their portfolio also includes Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical development, designed to enhance clinical pregnancy and live birth outcomes for women undergoing in vitro fertilization. Founded in 2012, ObsEva S.A. operates from its headquarters in Geneva, Switzerland.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 11:07 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2021 | May 6, 2021 | -$0.29-3.57% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
13 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CHF 403.30+CHF 1.60 (+0.4%)
Roche Holding AG’s quoted price sits in the upper half of its reported 52-week range, 0.64% below the high.
CHF 133.62+CHF 1.32 (+1.0%)
Novartis AG’s quoted price sits in the upper half of its reported 52-week range, 0.65% below the high.
$14.20+$0.34 (+2.45%)
Korro Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 66.74% below the high.
$2.06+$0.07 (+3.52%)
TuHURA Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 39.94% below the high.
$1.06-$0.06 (-5.36%)
Millendo Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 6.19% below the high.
$0.26-$0.01 (-3.13%)
Applied Molecular Transport Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$6.37-$0.41 (-5.98%)
Cyclacel Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.93% below the high.
$0.39+$0.03 (+8.48%)
Apexigen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.35% below the high.
